[go: up one dir, main page]

DE69424406D1 - Arzneistoffzusammensetzung, die ein nukleinsäurecopolymer enthält - Google Patents

Arzneistoffzusammensetzung, die ein nukleinsäurecopolymer enthält

Info

Publication number
DE69424406D1
DE69424406D1 DE69424406T DE69424406T DE69424406D1 DE 69424406 D1 DE69424406 D1 DE 69424406D1 DE 69424406 T DE69424406 T DE 69424406T DE 69424406 T DE69424406 T DE 69424406T DE 69424406 D1 DE69424406 D1 DE 69424406D1
Authority
DE
Germany
Prior art keywords
dioleylglycerol
nucleic acid
composition containing
acid copolymer
medicinal composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69424406T
Other languages
English (en)
Other versions
DE69424406T2 (de
Inventor
Junichi Yano
Tadaaki Ohgi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of DE69424406D1 publication Critical patent/DE69424406D1/de
Application granted granted Critical
Publication of DE69424406T2 publication Critical patent/DE69424406T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02—Monothiocarbamic acids; Derivatives thereof
    • C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4075—Esters with hydroxyalkyl compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69424406T 1993-02-19 1994-02-17 Arzneistoffzusammensetzung, die ein nukleinsäurecopolymer enthält Expired - Fee Related DE69424406T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP5493993 1993-02-19
PCT/JP1994/000238 WO1994018987A1 (en) 1993-02-19 1994-02-17 Drug composition containing nucleic acid copolymer

Publications (2)

Publication Number Publication Date
DE69424406D1 true DE69424406D1 (de) 2000-06-15
DE69424406T2 DE69424406T2 (de) 2000-10-26

Family

ID=12984615

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69424406T Expired - Fee Related DE69424406T2 (de) 1993-02-19 1994-02-17 Arzneistoffzusammensetzung, die ein nukleinsäurecopolymer enthält
DE69422163T Expired - Lifetime DE69422163T2 (de) 1993-02-19 1994-02-17 Glycerolderivat, vorrichtung und pharmazeutische zusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69422163T Expired - Lifetime DE69422163T2 (de) 1993-02-19 1994-02-17 Glycerolderivat, vorrichtung und pharmazeutische zusammensetzung

Country Status (11)

Country Link
US (2) US5705188A (de)
EP (2) EP0685457B1 (de)
JP (1) JP3189279B2 (de)
KR (2) KR100334858B1 (de)
AT (2) ATE187713T1 (de)
AU (2) AU6044994A (de)
CA (2) CA2156288C (de)
DE (2) DE69424406T2 (de)
ES (1) ES2142934T3 (de)
RU (2) RU2143903C1 (de)
WO (2) WO1994019314A1 (de)

Families Citing this family (287)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5799996A (en) * 1995-05-26 1996-12-11 Cell Genesys, Inc. Delivery vehicles comprising stable lipid/nucleic acid compl exes
WO1996040726A1 (en) * 1995-06-07 1996-12-19 Genta Incorporated Novel carbamate-based cationic lipids
AU705549B2 (en) * 1995-06-07 1999-05-27 Promega Biosciences, Inc. Phosphonic acid-based cationic lipids
CA2261987C (en) * 1996-07-22 2008-09-30 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Vectors for inhibiting hiv and tumor growth
FR2759367A1 (fr) * 1997-02-10 1998-08-14 Transgene Sa Glycerolipides cationiques et complexes de glycerolipides cationiques et de substances actives, notamment pour la transfection de cellules
FR2759382A1 (fr) * 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
US6716625B1 (en) 1997-04-16 2004-04-06 Claude Selitrennikoff Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
WO1999001579A1 (en) 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
TW524693B (en) * 1997-10-16 2003-03-21 Nippon Shinyaku Co Ltd Cancer cell nuclease activator
MY134896A (en) 1998-03-24 2007-12-31 Nippon Shinyaku Co Ltd Therapeutic agent for hepatitis
US6043390A (en) * 1998-04-03 2000-03-28 The Regents Of The University Of California Pentaerythritol lipid derivatives and nucleic-acid complexes
JP2002515514A (ja) 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの局所送逹のための組成物及び方法
EP1080103A4 (de) * 1998-05-21 2003-07-02 Isis Pharmaceuticals Inc Zubereitungen und verfahren zur nicht-parenteralen verabreichung von oligonukleotiden
CN1166366C (zh) 1998-05-25 2004-09-15 日本新药株式会社 含有核酸的复合物制剂的制备方法
ID29546A (id) * 1999-02-15 2001-09-06 Nippon Shinyaku Co Ltd Polinukleotida dengan rantai yang diperpendek dan metode pembuatannya
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
WO2001042200A1 (en) * 1999-12-10 2001-06-14 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
US20030134420A1 (en) * 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) * 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US7427394B2 (en) * 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US20020137076A1 (en) * 2000-11-28 2002-09-26 Shultz John W. RNA polymers and uses thereof
GB0106041D0 (en) * 2001-03-12 2001-05-02 Cancer Res Ventures Ltd Lipids and liposomes
EP2270024B1 (de) 2001-06-21 2018-10-24 Ionis Pharmaceuticals, Inc. Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
NZ566396A (en) 2001-10-09 2009-07-31 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
US20030165954A1 (en) 2002-01-09 2003-09-04 Third Wave Technologies, Inc. Cancer profiles
DE10207177A1 (de) * 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
US20060193905A1 (en) * 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
WO2004024919A1 (en) * 2002-09-13 2004-03-25 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
US20050196382A1 (en) * 2002-09-13 2005-09-08 Replicor, Inc. Antiviral oligonucleotides targeting viral families
WO2004031350A2 (en) 2002-09-26 2004-04-15 Amgen, Inc. Modulation of forkhead box o1a expression
AU2003294281B2 (en) 2002-11-13 2010-05-20 Kastle Therapeutics, Llc Antisense modulation of apolipoprotein B expression
PT2336318E (pt) 2002-11-13 2013-06-12 Genzyme Corp Modulação anti-sentido da expressão de apolipoproteína b
WO2004071453A2 (en) 2003-02-13 2004-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
CA2527301A1 (en) * 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. Oligonucleic acid-bearing composite and pharmaceutical composition containing the composite
US20080020990A1 (en) * 2003-05-30 2008-01-24 Nippon Shinyaku Co., Ltd. Oligo Double-Stranded Rna Inhibiting the Expression of Bcl-2 and Pharmaceutical Composition Containing the Same
JP2007516693A (ja) 2003-06-09 2007-06-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 癌の治療および診断のための組成物および方法
EP1648914A4 (de) 2003-07-31 2009-12-16 Regulus Therapeutics Inc Oligomere verbindungen und zusammensetzungen zur verwendung bei der modulierung von kleinen nicht-kodienderen rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
US7960350B2 (en) 2003-10-24 2011-06-14 Ader Enterprises, Inc. Composition and method for the treatment of eye disease
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
ES2423060T3 (es) * 2004-03-12 2013-09-17 Alnylam Pharmaceuticals, Inc. Agentes iRNA que tienen como diana al VEGF
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US7807647B2 (en) * 2004-06-01 2010-10-05 Pronai Therapeutics, Inc. Methods and compositions for cancer therapy
US8815599B2 (en) 2004-06-01 2014-08-26 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7498315B2 (en) * 2004-06-01 2009-03-03 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US7297786B2 (en) * 2004-07-09 2007-11-20 University Of Iowa Research Foundation RNA interference in respiratory epitheial cells
WO2006022325A1 (ja) * 2004-08-26 2006-03-02 Nippon Shinyaku Co., Ltd. ガラクトース誘導体、薬物担体及び医薬組成物
KR100699279B1 (ko) * 2005-04-28 2007-03-23 학교법인 포항공과대학교 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법
US7973084B2 (en) 2005-04-28 2011-07-05 Postech Academy-Industrial Foundation Molecular transporters based on alditol or inositol and processes for the preparation thereof
WO2006129594A1 (ja) 2005-05-30 2006-12-07 Nippon Shinyaku Co., Ltd. 核酸含有複合体製剤の製造方法
WO2006138275A2 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
KR100789323B1 (ko) * 2005-07-20 2007-12-28 주식회사 엔지켐 글리세롤 유도체의 위치 선택적 제조방법 및 그 중간체
WO2007033187A2 (en) 2005-09-12 2007-03-22 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
ME02226B (me) 2005-10-31 2016-02-20 Oncomed Pharm Inc Sastavi i postupci za dijagnozu i tretman raka
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2009513716A (ja) * 2005-11-01 2009-04-02 アルナイラム ファーマシューティカルズ インコーポレイテッド ＲＮＡｉによるインフルエンザウイルス複製の抑制
WO2007064857A2 (en) 2005-12-01 2007-06-07 Pronai Therapeutics, Inc. Amphoteric liposome formulation
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
KR20080106437A (ko) * 2006-03-01 2008-12-05 니뽄 신야쿠 가부시키가이샤 갈락토스 유도체, 약물 담체 및 의약 조성물
JP5704741B2 (ja) 2006-03-31 2015-04-22 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇ５遺伝子発現の抑制のための組成物および方法
WO2007127919A2 (en) * 2006-04-28 2007-11-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a gene from the jc virus
JP2009537153A (ja) 2006-05-19 2009-10-29 アルニラム ファーマシューティカルズ， インコーポレイテッド ＡｈａのＲＮＡｉ調節およびその治療上の使用
US7888498B2 (en) * 2006-05-22 2011-02-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of IKK-B gene
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer
WO2007143659A2 (en) * 2006-06-05 2007-12-13 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
EP2046266A4 (de) 2006-07-21 2009-11-04 Massachusetts Inst Technology Endmodizifierte poly(beta-amino-ester) und ihre verwendung
US20080261216A1 (en) * 2006-09-08 2008-10-23 The Regents Of The University Of Michigan HERV Group II Viruses In Lymphoma And Cancer
US20100136537A1 (en) * 2006-10-10 2010-06-03 The Regents Of The University Of Michigan Photoreceptor precursor cells
WO2008086807A2 (en) * 2007-01-19 2008-07-24 Exiqon A/S Mediated cellular delivery of lna oligonucleotides
WO2008092002A2 (en) * 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008096690A1 (ja) 2007-02-05 2008-08-14 Nippon Shinyaku Co., Ltd. ポリエチレングリコール誘導体
WO2008109806A2 (en) * 2007-03-08 2008-09-12 Massachusetts Institute Of Technology Electrostatic coating of particles for drug delivery
AP2014007971A0 (en) 2007-03-29 2014-09-30 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expressionof a gene from the ebola
JP2010527375A (ja) * 2007-05-15 2010-08-12 ヘリコン セラピューティクス，インコーポレイテッド Ｇｐｒ１２の阻害による認知障害の治療方法
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) * 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US8158757B2 (en) 2007-07-02 2012-04-17 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
EP2167689B1 (de) 2007-07-06 2012-10-31 The Regents Of The University Of Michigan Wiederkehrende genfusionen bei prostatakrebs
US8084057B2 (en) 2007-07-17 2011-12-27 University Of Massachusetts Compositions and methods for wound healing
US8865178B2 (en) 2007-07-17 2014-10-21 University Of Massachusetts Compositions and methods for wound healing
CA2695674A1 (en) 2007-08-16 2009-02-26 Metabolon, Inc. Metabolomic profiling of prostate cancer
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
EP2848688A1 (de) 2007-12-10 2015-03-18 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
CA2709875C (en) * 2008-01-02 2019-07-16 Tekmira Pharmaceuticals Corporation Improved compositions and methods for the delivery of nucleic acids
US20110118340A1 (en) * 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
MX2010009611A (es) 2008-03-05 2010-12-15 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion de genes eg5 y vegf.
WO2009129385A1 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
WO2009129387A2 (en) * 2008-04-16 2009-10-22 Abbott Laboratories Cationic lipids and uses thereof
CN102065901B (zh) * 2008-06-19 2013-03-06 日本新药株式会社 药物载体
WO2010042281A2 (en) 2008-08-25 2010-04-15 Excaliard Pharmaceuticals Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8318693B2 (en) 2008-09-02 2012-11-27 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mutant EGFR gene
EP3584320A1 (de) 2008-09-25 2019-12-25 Alnylam Pharmaceuticals, Inc. Zusammensetzungen aus lipidformulierungen und verfahren zur hemmung der serum-amyloid-a-genexpression
ES2663536T3 (es) 2008-09-26 2018-04-13 Oncomed Pharmaceuticals, Inc. Agentes que se unen a receptores frizzled y usos de los mismos
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
CA2747770C (en) * 2008-12-22 2017-10-17 Kouji Yokoyama Melanin production inhibitor
BRPI1004572A2 (pt) 2009-01-09 2016-04-05 Univ Michigan "fusões genéticas recorrentes em câncer
US20120041051A1 (en) 2009-02-26 2012-02-16 Kevin Fitzgerald Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
WO2010105209A1 (en) 2009-03-12 2010-09-16 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
EP2756845B1 (de) 2009-04-03 2017-03-15 Dicerna Pharmaceuticals, Inc. Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
US20100272824A1 (en) * 2009-04-16 2010-10-28 The Texas A&M University System Compositions and methods for preventing and monitoring disease
CN102573847A (zh) 2009-05-14 2012-07-11 总医院公司 治疗退化性及缺血性疾病的方法和组合物
WO2010141630A1 (en) 2009-06-03 2010-12-09 University Of Southern California Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway
BR212012000255U2 (pt) 2009-07-09 2015-11-03 Marina Biotech Inc lipossomas anfotéricos compreendendo imino lípidos.
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US9056114B2 (en) 2009-08-28 2015-06-16 Jeffrey P. Erickson Chemical induction of lactation
EP2490699A1 (de) 2009-10-20 2012-08-29 Santaris Pharma A/S Orale freisetzung von therapeutisch wirksamen lna-oligonukleotiden
EP2506857B1 (de) 2009-12-01 2018-02-14 Translate Bio, Inc. Verabreichung von mrna zur vermehrung von proteinen und enzymen bei humangenetischen erkrankungen
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
AU2011237630B2 (en) 2010-04-06 2016-01-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
US9125931B2 (en) 2010-04-06 2015-09-08 Massachusetts Institute Of Technology Post-transcriptional regulation of RNA-related processes using encoded protein-binding RNA aptamers
EP2576579B1 (de) 2010-06-02 2018-08-08 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von leberfibrose
JP5893611B2 (ja) * 2010-06-03 2016-03-23 アルニラム・ファーマシューティカルズ・インコーポレーテッド 活性剤の送達のための生分解性脂質
EP2609135A4 (de) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(beta-amino-alkohole), ihre herstellung und verwendungen davon
CN110123830A (zh) 2010-11-09 2019-08-16 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
US9193973B2 (en) 2010-12-10 2015-11-24 Alynylam Pharmaceuticals, Inc. Compositions and methods for increasing erythropoietin (EPO) production
WO2012079046A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
ES2729956T3 (es) 2011-02-02 2019-11-07 Excaliard Pharmaceuticals Inc Compuestos antisentido dirigidos al factor de crecimiento de tejido conectivo (ctgf) para su uso en un procedimiento de tratamiento de queloides o cicatrices hipertróficas
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
CA2831284C (en) 2011-03-29 2023-12-12 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of tmprss6 gene
US10086043B2 (en) 2011-04-03 2018-10-02 The General Hospital Corporation Efficient protein expression in vivo using modified RNA (MOD-RNA)
TR201910686T4 (tr) 2011-06-08 2019-08-21 Translate Bio Inc Mrna iletimine yönelik lipit nanopartikül bileşimleri ve yöntemler.
WO2012177906A1 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
SG10201913683WA (en) 2011-06-21 2020-03-30 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
EP4134433A1 (de) 2011-06-23 2023-02-15 Alnylam Pharmaceuticals, Inc. Serpina1-sirnas: materialzusammensetzungen und behandlungsverfahren
WO2013019857A2 (en) 2011-08-01 2013-02-07 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
US9126966B2 (en) 2011-08-31 2015-09-08 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use thereof
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
CA2856116A1 (en) 2011-11-17 2013-05-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Therapeutic rna switches compositions and methods of use
AU2012347637B2 (en) 2011-12-07 2017-09-14 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US20150267192A1 (en) 2012-06-08 2015-09-24 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9873674B2 (en) 2012-09-21 2018-01-23 Cornell University C-Rel inhibitors and uses thereof
EP2911691B1 (de) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln
EP3336187A1 (de) 2012-12-05 2018-06-20 Alnylam Pharmaceuticals, Inc. Pcsk9-irna-zusammensetzungen und verfahren zur verwendung davon
EP3434774A1 (de) 2013-01-17 2019-01-30 ModernaTX, Inc. Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen
WO2014112280A1 (ja) * 2013-01-17 2014-07-24 学校法人日本大学 油性組成物及び増粘又はゲル形成剤
CA2899353A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
WO2014184655A1 (en) 2013-02-07 2014-11-20 Olympic Seafood As Methods for using crustacean phospholipid-peptide-protein complexes
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
UA117008C2 (uk) 2013-03-14 2018-06-11 Шир Хьюман Дженетік Терапіс, Інк. IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ
ES2708561T3 (es) 2013-03-14 2019-04-10 Translate Bio Inc Métodos para la purificación de ARN mensajero
EP3312281A3 (de) 2013-03-14 2018-06-27 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
WO2014182661A2 (en) 2013-05-06 2014-11-13 Alnylam Pharmaceuticals, Inc Dosages and methods for delivering lipid formulated nucleic acid molecules
JP6495250B2 (ja) 2013-05-22 2019-04-03 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＳＥＲＰＩＮＡ１ ｉＲＮＡ組成物およびその使用方法
EP3587578A1 (de) 2013-05-22 2020-01-01 Alnylam Pharmaceuticals, Inc. Tmprss6-irna-zusammensetzungen und verfahren zur verwendung davon
US10126305B2 (en) 2013-06-25 2018-11-13 University of Pittsburg—Of the Commonwealth System of Higher Education Proteomic biomarkers of sepsis in elderly patients
MX385871B (es) 2013-10-02 2025-03-18 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen lect2.
KR20220159478A (ko) 2013-10-04 2022-12-02 알닐람 파마슈티칼스 인코포레이티드 Ａｌａｓ1 유전자의 발현을 억제하기 위한 조성물 및 방법
BR112016009077A2 (pt) 2013-10-22 2017-09-19 Shire Human Genetic Therapies Formulações lipídicas para fornecimento de rna mensageiro
AU2014340092B2 (en) 2013-10-22 2019-09-19 Translate Bio, Inc. mRNA therapy for Argininosuccinate Synthetase Deficiency
EP3574923A1 (de) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna-therapie für phenylketonurie
IL314045A (en) 2013-12-12 2024-09-01 Alnylam Pharmaceuticals Inc Complement component irna compositions and methods of use thereof
ES2774968T3 (es) 2013-12-19 2020-07-23 Novartis Ag Lípidos y composiciones lipídicas para la administración de agentes activos
CN118845818A (zh) 2014-02-11 2024-10-29 阿尔尼拉姆医药品有限公司 己酮糖激酶（KHK）iRNA组合物及其使用方法
JP6571679B2 (ja) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
WO2015175510A1 (en) 2014-05-12 2015-11-19 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a serpinc1-associated disorder
SG11201609376SA (en) 2014-05-22 2016-12-29 Alnylam Pharmaceuticals Inc Angiotensinogen (agt) irna compositions and methods of use thereof
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3148552B1 (de) 2014-05-30 2019-07-31 Translate Bio, Inc. Biologisch abbaubare lipide zur freisetzung von nukleinsäuren
US10138213B2 (en) 2014-06-24 2018-11-27 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN106794141B (zh) 2014-07-16 2021-05-28 诺华股份有限公司 将核酸包封在脂质纳米粒主体中的方法
WO2016024205A1 (en) 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016036724A1 (en) 2014-09-02 2016-03-10 The Texas A&M University System Method of treating organophosphate intoxication
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
JOP20200115A1 (ar) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3207138B1 (de) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
EP3212794B1 (de) 2014-10-30 2021-04-07 Genzyme Corporation Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
WO2016081444A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
AU2015362630B2 (en) 2014-12-15 2021-09-02 Dicerna Pharmaceuticals, Inc. Ligand-modified double-stranded nucleic acids
CA2976445A1 (en) 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
MX2017012610A (es) 2015-04-08 2018-03-16 Alnylam Pharmaceuticals Inc Composiciones y metodos para inhibir la expresion del gen lect2.
TWI723986B (zh) 2015-04-13 2021-04-11 美商阿尼拉製藥公司 類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其用途方法
CA2984636A1 (en) 2015-05-06 2016-11-10 Alnylam Pharmaceuticals, Inc. Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
US9861597B2 (en) 2015-05-19 2018-01-09 Penn State Research Foundation Gluconate-based compositions as a neonate anticonvulsant
EP3307316A1 (de) 2015-06-12 2018-04-18 Alnylam Pharmaceuticals, Inc. Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
WO2016205323A1 (en) 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
CA2990172A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
CA3036409C (en) 2015-09-08 2023-07-11 Erik J. Sontheimer Dnase h activity of neisseria meningitidis cas9
WO2017048843A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the alas1 gene
WO2017048620A1 (en) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
WO2017067592A1 (en) 2015-10-21 2017-04-27 Biontech Ag Cytotoxic immunostimulating particles and uses thereof
EP3386518A1 (de) 2015-12-07 2018-10-17 Genzyme Corporation Verfahren und zusammensetzungen zur behandlung von serpinc1-assoziierten erkrankungen
WO2017100542A1 (en) 2015-12-10 2017-06-15 Alnylam Pharmaceuticals, Inc. Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
WO2017123787A1 (en) 2016-01-13 2017-07-20 University Of Massachusetts Antihelminthic medications for pathogenic nematodes
US10322171B2 (en) 2016-02-19 2019-06-18 The Board Of Regents Of The University Of Texas Systems Vaccine with reduced enhancement of viral infection
CN109152848B (zh) 2016-03-15 2022-12-09 马萨诸塞大学 抗-crispr化合物以及使用方法
US10213503B2 (en) 2016-05-19 2019-02-26 The Board Of Trustees Of The University Of Texas System Attenuated Burkholderia mallei strain which protects against pathogenic Burkholderia infections, vaccine containing and use thereof
JP2019518028A (ja) 2016-06-10 2019-06-27 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 補体成分Ｃ５ｉＲＮＡ組成物及び発作性夜間血色素尿症（ＰＮＨ）を処置するためのその使用方法
WO2018013509A1 (en) 2016-07-11 2018-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
TW202313978A (zh) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
WO2018112320A1 (en) 2016-12-16 2018-06-21 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
US11241436B2 (en) 2017-01-25 2022-02-08 Northwestern University Autophagy inducers for treatment of CNS conditions
CA3054062A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Novel codon-optimized cftr mrna
EP3621645A4 (de) 2017-05-10 2021-01-27 University of Massachusetts Bivalente dengue-/hepatitis-b-impfstoffe
EP3624824B1 (de) 2017-05-16 2024-07-10 Translate Bio, Inc. Codonoptimierter mrna, die cftr codiert, zur verwendung in der behandlung von zystischer fibrose
AU2018297262A1 (en) 2017-07-06 2020-02-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of alpha-ENaC and methods of use
JP7277432B2 (ja) 2017-07-13 2023-05-19 アルナイラム ファーマシューティカルズ， インコーポレイテッド 乳酸脱水素酵素Ａ（ＬＤＨＡ）ｉＲＮＡ組成物及びその使用方法
US11331319B2 (en) 2017-09-28 2022-05-17 University Of Massachusetts Combination treatment for neuropsychiatric disorders
US11464860B2 (en) 2017-10-27 2022-10-11 Massachusetts Institute Of Technology Poly (beta-amino esters) and uses thereof
US20200385719A1 (en) 2017-11-16 2020-12-10 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019103967A1 (en) 2017-11-22 2019-05-31 The Regents Of The University Of Michigan Compositions and methods for treating cancer
CN111727252A (zh) 2017-12-18 2020-09-29 阿尔尼拉姆医药品有限公司 高速泳动族盒-1（HMGB1）iRNA组合物及其使用方法
JP7381469B2 (ja) 2018-01-03 2023-11-15 ザ、ペン、ステート、リサーチ、ファウンデーション 新生児抗痙攣薬としてのグルコースオキシダーゼ組成物
KR20210008369A (ko) 2018-05-11 2021-01-21 알파 아노메리끄 에스아에스 7'-5'-알파-아노머-이중고리상 당 뉴클레오시드를 포함하는 올리고뉴클레오티드 컨쥬게이트
MX2021000099A (es) * 2018-06-29 2021-03-25 Basf Se Sales de esteramina.
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
US11987792B2 (en) 2018-08-16 2024-05-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the LECT2 gene
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
CA3117781A1 (en) 2018-10-26 2020-04-30 Massachusetts Institute Of Technology Polymer-lipids and compositions
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
WO2021014389A1 (en) 2019-07-24 2021-01-28 H. Lundbeck A/S Anti-mglur5 antibodies and uses thereof
EP4013870A1 (de) 2019-08-13 2022-06-22 Alnylam Pharmaceuticals, Inc. Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
BR112022003860A2 (pt) 2019-09-03 2022-08-16 Alnylam Pharmaceuticals Inc Composições e métodos para inibir a expressão do gene lect2
EP4038189A1 (de) 2019-10-04 2022-08-10 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
CN114728018B (zh) 2019-11-01 2024-07-19 阿尔尼拉姆医药品有限公司 亨廷顿(HTT)iRNA药剂组合物及其使用方法
WO2021087325A1 (en) 2019-11-01 2021-05-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
US20230056569A1 (en) 2019-11-22 2023-02-23 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
MX2022006433A (es) 2019-12-13 2022-06-23 Alnylam Pharmaceuticals Inc Composiciones de agentes de acido ribonucleico de interferencia (arni) del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72) y metodos de uso de los mismos.
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
EP4103714A1 (de) 2020-02-10 2022-12-21 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zum unterdrücken der vegf-a expression
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
EP4114947A1 (de) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Komplementkomponenten-c3-irna-zusammensetzungen und verfahren zur verwendung davon zur behandlung oder prävention von mit komplementkomponenten-c3-assoziierten erkrankungen
EP4121534A1 (de) 2020-03-18 2023-01-25 Alnylam Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt)
WO2021195307A1 (en) 2020-03-26 2021-09-30 Alnylam Pharmaceuticals, Inc. Coronavirus irna compositions and methods of use thereof
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
JP2023520582A (ja) 2020-04-06 2023-05-17 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｍｙｏｃ発現をサイレンシングするための組成物および方法
US20230159933A1 (en) 2020-04-07 2023-05-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing scn9a expression
EP4133076A1 (de) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
EP4133077A1 (de) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Irna-zusammensetzungen mit transmembran-serinprotease 2 (tmprss2) und verfahren zur verwendung davon
WO2021222065A1 (en) 2020-04-27 2021-11-04 Alnylam Pharmaceuticals, Inc. Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
US20230183707A1 (en) 2020-05-21 2023-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
WO2021252557A1 (en) 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
EP4217489A1 (de) 2020-09-24 2023-08-02 Alnylam Pharmaceuticals, Inc. Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
EP4225917A1 (de) 2020-10-05 2023-08-16 Alnylam Pharmaceuticals, Inc. G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
CA3198823A1 (en) 2020-10-21 2022-04-28 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
WO2022087329A1 (en) 2020-10-23 2022-04-28 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
TW202237150A (zh) 2020-12-01 2022-10-01 美商艾拉倫製藥股份有限公司 用於抑制ｈａｏ１（羥基酸氧化酶１（乙醇酸氧化酶））基因表現的方法及組成物
KR20230146048A (ko) 2021-02-12 2023-10-18 알닐람 파마슈티칼스 인코포레이티드 슈퍼옥사이드 디스뮤타제 1(sod1) irna 조성물 및 슈퍼옥사이드 디스뮤타제 1- (sod1-) 관련 신경퇴행성 질환을 치료하거나 예방하기 위한 이의 사용 방법
EP4298220A1 (de) 2021-02-25 2024-01-03 Alnylam Pharmaceuticals, Inc. Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
BR112023019981A2 (pt) 2021-03-29 2023-12-12 Alnylam Pharmaceuticals Inc Composições do agente irna de huntingtina (htt) e métodos de uso das mesmas
JP2024522068A (ja) 2021-05-18 2024-06-11 アルナイラム ファーマシューティカルズ， インコーポレイテッド ナトリウム－グルコース共輸送体２（ｓｇｌｔ２）ｉｒｎａ組成物およびその使用方法
EP4347822A2 (de) 2021-06-04 2024-04-10 Alnylam Pharmaceuticals, Inc. Irna-wirkstoffzusammensetzungen mit offenem leserahmen 72 (c9orf72) auf menschlichem chromosom 9 und verfahren zur verwendung davon
US20240376499A1 (en) 2021-07-09 2024-11-14 University Of Massachusetts Modular prime editing systems for genome engineering
TW202333748A (zh) 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 用於處置具有或有風險發展非原發性高草酸鹽尿疾病或病症的個體的方法及組成物
JP2024541974A (ja) 2021-10-29 2024-11-13 アルナイラム ファーマシューティカルズ， インコーポレイテッド ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
EP4431101A1 (de) 2021-11-10 2024-09-18 Tokyo Metropolitan Institute of Medical Science Therapeutikum für refraktäre virale infektionen
EP4469575A2 (de) 2022-01-24 2024-12-04 Alnylam Pharmaceuticals, Inc. Enzym-irna-wirkstoffzusammensetzungen für den heparinsulfatbiosyntheseweg und verfahren zur verwendung davon
CN114907243B (zh) * 2022-02-28 2023-10-27 东南大学 一种可离子化脂质、其组合物及应用
CN116120198B (zh) * 2022-03-21 2024-03-15 苏州科锐迈德生物医药科技有限公司 具有甘油骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN116354836A (zh) * 2022-03-25 2023-06-30 深圳市新合生物医疗科技有限公司 阳离子脂质化合物及其制备方法和应用、以及mRNA递送系统
EP4532702A1 (de) 2022-06-02 2025-04-09 University of Massachusetts Chimere prime-editorsysteme mit hochgenauer nukleotidpolymerase
AU2023314109A1 (en) 2022-07-25 2025-02-06 University Of Massachusetts Nucleic acid antisense oligomer readthrough of nonsense codons
TW202424193A (zh) 2022-09-15 2024-06-16 美商艾拉倫製藥股份有限公司 第１３型１７β－羥基類固醇去氫酶（ＨＳＤ１７Ｂ１３）ｉＲＮＡ組成物及其使用方法
WO2025038864A1 (en) * 2023-08-16 2025-02-20 Beam Therapeutics Inc. Ionizable lipids with linear head groups
CN117820149B (zh) * 2023-12-29 2025-01-07 北京剂泰医药科技有限公司 可电离脂质化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5933222A (ja) * 1982-08-20 1984-02-23 Mitsui Toatsu Chem Inc 合成デオキシリボ核酸を有効成分とする抗腫瘍剤
JPS60104066A (ja) * 1983-11-10 1985-06-08 Ono Pharmaceut Co Ltd グリセリン誘導体
EP0164397B1 (de) * 1983-11-21 1990-07-04 The Regents Of The University Of Minnesota Gepuffertes polyol-hormones gemisch zur verwendung bei chronischer parenteraler hormonverabreichung
JPS61103824A (ja) * 1984-10-27 1986-05-22 Nippon Kayaku Co Ltd ポリリボイノシン酸・ポリリボシチヂル酸・ポリ−レ−リジン複合体の注射用製剤の新規調製法
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
DE3612636C2 (de) * 1985-04-15 1993-11-18 Asahi Chemical Ind Nucleosid-Phospholipid-Komplexe
JP2527346B2 (ja) * 1987-01-27 1996-08-21 昭 梶 抗ウイルス剤
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US4961932A (en) * 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
US5030454A (en) * 1987-10-26 1991-07-09 Alza Corporation Method for delivering drug in tiny pills in liquid carrier
US4882147A (en) * 1987-12-16 1989-11-21 The Research Foundation Of State University Of New York Novel polynucleotide analogs, methods for inhibiting nucleic acid polymerases and methods for inducing synthesis of interferon
US5231085A (en) * 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms
DE68904874T2 (de) * 1988-10-31 1993-07-15 Sandoz Nutrition Ltd Organische verbindungen.
JPH03240795A (ja) * 1990-02-15 1991-10-28 Ajinomoto Co Inc 新規オリゴヌクレオチド誘導体及び抗ウイルス剤への使用
JP2604268B2 (ja) * 1990-04-09 1997-04-30 富士写真フイルム株式会社 ペプチド誘導体両親媒性化合物、その中間体、ペプチド誘導体両親媒性化合物を用いたリポソームおよび薄膜
EP0468520A3 (en) * 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
JPH04352724A (ja) * 1990-07-27 1992-12-07 Mitsui Toatsu Chem Inc 免疫調節型治療剤
JPH04210921A (ja) * 1991-02-08 1992-08-03 Asahi Chem Ind Co Ltd 新規リン脂質・ヌクレオシド誘導体を有効成分とする抗腫瘍剤

Also Published As

Publication number Publication date
US6020317A (en) 2000-02-01
DE69422163T2 (de) 2000-06-15
KR960700730A (ko) 1996-02-24
KR960700997A (ko) 1996-02-24
ATE192657T1 (de) 2000-05-15
JP3189279B2 (ja) 2001-07-16
AU6044994A (en) 1994-09-14
US5705188A (en) 1998-01-06
RU2123492C1 (ru) 1998-12-20
CA2156289A1 (en) 1994-09-01
RU2143903C1 (ru) 2000-01-10
KR100334858B1 (ko) 2006-01-27
CA2156289C (en) 2006-01-03
ATE187713T1 (de) 2000-01-15
EP0685234A4 (de) 1997-10-22
EP0685457A1 (de) 1995-12-06
AU6045094A (en) 1994-09-14
CA2156288C (en) 2005-10-18
WO1994019314A1 (en) 1994-09-01
EP0685457B1 (de) 1999-12-15
ES2142934T3 (es) 2000-05-01
KR100283601B1 (ko) 2001-03-02
DE69424406T2 (de) 2000-10-26
EP0685234B1 (de) 2000-05-10
DE69422163D1 (de) 2000-01-20
WO1994018987A1 (en) 1994-09-01
CA2156288A1 (en) 1994-09-01
EP0685234A1 (de) 1995-12-06
EP0685457A4 (de) 1996-09-18

Similar Documents

Publication Publication Date Title
DE69424406D1 (de) Arzneistoffzusammensetzung, die ein nukleinsäurecopolymer enthält
CY2008012I2 (el) Υδροξυεστερες ραπαμυκινης, διαδικασια για τη παρασκευη τους και φαρμακευτικες συνθεσεις περιεχουσες αυτες
FI954329L (fi) Farmaseuttisina aineina käytettäviä nukleiinihappoja
FI954767L (fi) Lipofiilisiä lääkeaineita sisältävä farmaseuttinen koostumus
FR2741066B1 (fr) Nouveaux agents de transfection et leurs applications pharmaceutiques
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
FI942095L (fi) Puhdistettuja hepariinifraktioita, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia
DE59008160D1 (de) Feste pharmazeutische Präparate und Verfahren zu ihrer Herstellung.
DE3863366D1 (de) Antibiotikum vermisporin, verfahren zu dessen herstellung und dasselbe als aktiver antibakterieller wirkstoff enthaltende pharmazeutische zusammensetzung.
DE3750913D1 (de) Karbostyrilderivate, Verfahren zu ihrer Herstellung, diese enthaltende pharmazeutische Zusammensetzungen und ihre Verwendung.
BR9812316A (pt) Formulações de camptotecina lipossÈmica
FI954111L (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
FI961536L (fi) Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste
DE3484925D1 (de) Pyrazolochinoline, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen.
ATA900894A (de) Pharmazeutische kompositionen zum vorbeugen und heilen von krebserkrankungen und verfahren zu ihrer herstellung
DE59308840D1 (de) Hochkonzentrierte wässrige Poly(acrylnitril)-Emulsionen und Verfahren zu ihrer Herstellung
FI961938L (fi) Uudet taksoidit, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
ATE264837T1 (de) N-guanidinalkylamide, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate
DE3766299D1 (de) 4-chinolon-3-carbonsaeurederivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
HUP9900317A3 (en) Pharmaceutical composition useful for nucleic acid transfection, and use thereof
FI960316L (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
ATA260590A (de) Glyzerinderivate, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
DE3674521D1 (de) 6-phenoxymethyl-4-hydroxytetrahydropyran-2-one, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte.
ATE250051T1 (de) Sulfonamid-substituierte benzopyranderivate, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltende pharmazeutische zubereitungen
FI951091L (fi) Uudet alkyyliaminoindaaniyhdisteet, menetelmät niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee